Mergers and acquisitions

#Haematology #Ipsen #Mergers and acquisitions #Oncology

Ipsen acquires Kartos Therapeutics in $450m deal 

Biopharmaceutical company Ipsen has agreed a deal to acquire Kartos Therapeutics, expanding its haemato-oncology late-stage pipeline.  Ipsen will pay $450 million upfront as per the terms of the agreement, with Kartos Therapeutics shareholders eligible to receive payments of up to $1.3 million subject to regulatory approval milestones and sales-based milestones. … Read More

#Business & Investment #News

#Bio-Techne #Merck #Mergers and acquisitions

Merck acquires Bio-Techne for $11.3 billion

Merck and Bio-Techne have agreed that Merck will acquire Bio-Techne for $73 per share, representing a total enterprise value of approximately $11.3 billion.  “This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our… Read More

#Business & Investment #Editor's Choice #News

#Acute Myeloid Leukaemia #Mergers and acquisitions

Thalia acquires Sanmirna and AML RNA therapy 

Biotechnology company Thalia Therapeutics has acquired Sanmirna Therapeutics and its clinical-stage cancer RNA therapy.  The acquisition catapults Thalia to a clinical-stage RNA therapeutics company, leveraging Sanmirna’s anti-microRNA-126 for the treatment of acute myeloid leukaemia.  The deal is believed to be worth £16.675 million ($21.984 million), encompassing an initial… Read More

#Business & Investment #News

#Eli Lilly #Immunology / Virology & Vaccines #Mergers and acquisitions

Lilly expansion aims to “prevent disease at its source”

Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million.  The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens… Read More

#Business & Investment #Editor's Choice #News

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

DDW Highlights: 12 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More

#Podcasts

Brain physiology
#Angelini Pharma #Biopharma #Brain #Mergers and acquisitions

Angelini Pharma acquires Catalyst to enter US market 

Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion.  Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market… Read More

#Business & Investment #News

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

This week in Drug Discovery (4 – 8 May) 

News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.  This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.  The top stories:    FDA moves… Read More

#News

business deal
#AI / data analytics / healthtech / informatics #Drug discovery #Mergers and acquisitions #Multi-omics

UCB to acquire IMIDomics’ Patient Insight Business  

Global pharmaceutical company UCB has acquired the Patient Insights Business of IMIDomics, giving it access to a large, multi-omics dataset for immunology studies.  IMIDomics’ Patient Insight Business includes over 18 years of clinical and molecular data generation. It integrates epidemiological information, clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples.  … Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

MRI of the brain
#Cell therapy #epilepsy #Mergers and acquisitions #Neurona Therapeutics #Neuroscience #UCB

UCB to acquire epilepsy specialists Neurona Therapeutics

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio.   Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.  UCB will pay… Read More

#Business & Investment #News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #Eli Lilly #Mergers and acquisitions

Lilly buys in vivo CAR-T developer Kelonia Therapeutics

Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion.  Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #CrossBridge Bio #Eli Lilly #Mergers and acquisitions

Antibody-drug conjugate company CrossBridge Bio acquired by Lilly

Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment.  CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

IgE antibody
#Allergy #Mergers and acquisitions #Novartis

Novartis acquires allergy experts Excellergy for $2 billion

Novartis has agreed to acquire Excellergy, a biotechnology company developing a novel class of allergy therapeutics, in a transaction with a total potential value of up to $2 billion in upfront and milestone payments.   Excellergy’s Exl-111 is a trifunctional effector cell response inhibitor (ECRI) designed to disarm… Read More

#Business & Investment #News

Narcolepsy
#Centessa Pharmaceuticals #Eli Lilly #Mergers and acquisitions

Lilly acquires sleep-wake disorders specialist Centessa

Eli Lilly has announced a definitive agreement under which it will acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront and a potential equity value of $1.5 billion.  Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the… Read More

#Business & Investment #News